Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$17.53 USD

17.53
5,608,806

+0.57 (3.36%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $17.55 +0.02 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

Zacks Equity Research

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

Zacks Equity Research

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.

Zacks Equity Research

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

Zacks Equity Research

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

by Zacks Equity Research

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

by Zacks Equity Research

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

Zacks Equity Research

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

Zacks Equity Research

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

Zacks Equity Research

Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of -2.94% and 0.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.